GlaxoSmithKline Files Two Melanoma Drugs for U.S., Europe Approvals

Published: Aug 06, 2012

GlaxoSmithKline Plc (GSK), the U.K.’s largest drugmaker, said it submitted two experimental melanoma medicines to regulators in the U.S. and Europe for approval following trials that it deemed successful two months ago. Glaxo filed dabrafenib with both the European Medicines Agency and the U.S. Food and Drug Administration, the London- based company said in a statement today. Glaxo is also applying for U.S. approval of trametinib, and will seek European clearance for trametinib in “coming months.”

Back to news